D. E. Shaw & Co., Inc. Arcturus Therapeutics Holdings Inc. Transaction History

D. E. Shaw & Co., Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$31.23 - $42.99 $1.98 Million - $2.73 Million	-63,440 Reduced 85.97%	10,355 $349,000
Q4 2023 Feb 14, 2024	BUY	$17.71 - $32.97 $516,529 - $961,603	29,166 Added 65.35%	73,795 $2.33 Million
Q3 2023 Nov 14, 2023	SELL	$25.44 - $37.35 $1.46 Million - $2.15 Million	-57,458 Reduced 56.28%	44,629 $1.14 Million
Q2 2023 Aug 14, 2023	BUY	$23.94 - $32.36 $2.44 Million - $3.3 Million	102,087 New	102,087 $2.93 Million
Q1 2022 May 16, 2022	SELL	$17.64 - $39.57 $2.26 Million - $5.08 Million	-128,363 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$34.2 - $47.56 $1.11 Million - $1.55 Million	32,597 Added 34.04%	128,363 $4.75 Million
Q3 2021 Nov 15, 2021	SELL	$27.88 - $58.25 $5.84 Million - $12.2 Million	-209,324 Reduced 68.61%	95,766 $4.58 Million
Q2 2021 Aug 16, 2021	BUY	$25.79 - $42.11 $5.81 Million - $9.48 Million	225,152 Added 281.66%	305,090 $10.3 Million
Q1 2021 May 17, 2021	BUY	$38.75 - $86.92 $3.1 Million - $6.95 Million	79,938 New	79,938 $3.3 Million
Q3 2020 Nov 16, 2020	SELL	$37.49 - $63.19 $220,216 - $371,178	-5,874 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.66 - $58.27 $74,364 - $342,277	5,874 New	5,874 $275,000

187

25.9M

320K

153K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $635M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.